Literature DB >> 24520903

Off-rate screening (ORS) by surface plasmon resonance. An efficient method to kinetically sample hit to lead chemical space from unpurified reaction products.

James B Murray1, Stephen D Roughley, Natalia Matassova, Paul A Brough.   

Abstract

The dissociation rate constant kd (off-rate) is the component of ligand-protein binding with the most significant potential to enhance compound potency. Here we provide theoretical and empirical data to show that this parameter can be determined accurately from unpurified reaction products containing designed test compounds. This screening protocol is amenable to parallel chemistry, provides efficiencies of time and materials, and complements existing methodologies for the hit-to-lead phase in fragment-based drug discovery.

Mesh:

Substances:

Year:  2014        PMID: 24520903     DOI: 10.1021/jm401848a

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

Review 1.  Biophysics in drug discovery: impact, challenges and opportunities.

Authors:  Jean-Paul Renaud; Chun-Wa Chung; U Helena Danielson; Ursula Egner; Michael Hennig; Roderick E Hubbard; Herbert Nar
Journal:  Nat Rev Drug Discov       Date:  2016-08-12       Impact factor: 84.694

Review 2.  Twenty years on: the impact of fragments on drug discovery.

Authors:  Daniel A Erlanson; Stephen W Fesik; Roderick E Hubbard; Wolfgang Jahnke; Harren Jhoti
Journal:  Nat Rev Drug Discov       Date:  2016-07-15       Impact factor: 84.694

3.  Activity-Directed Synthesis of Inhibitors of the p53/hDM2 Protein-Protein Interaction.

Authors:  Adam I Green; Fruzsina Hobor; Christopher P Tinworth; Stuart Warriner; Andrew J Wilson; Adam Nelson
Journal:  Chemistry       Date:  2020-08-04       Impact factor: 5.236

4.  The Role of Ligand Rebinding and Facilitated Dissociation on the Characterization of Dissociation Rates by Surface Plasmon Resonance (SPR) and Benchmarking Performance Metrics.

Authors:  Aykut Erbaş; Fatih Inci
Journal:  Methods Mol Biol       Date:  2022

5.  Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation.

Authors:  Charles E Hendrick; Jeff R Jorgensen; Charu Chaudhry; Iulia I Strambeanu; Jean-Francois Brazeau; Jamie Schiffer; Zhicai Shi; Jennifer D Venable; Scott E Wolkenberg
Journal:  ACS Med Chem Lett       Date:  2022-06-20       Impact factor: 4.632

6.  Fragment library screening identifies hits that bind to the non-catalytic surface of Pseudomonas aeruginosa DsbA1.

Authors:  Biswaranjan Mohanty; Kieran Rimmer; Róisín M McMahon; Stephen J Headey; Mansha Vazirani; Stephen R Shouldice; Mathieu Coinçon; Stephanie Tay; Craig J Morton; Jamie S Simpson; Jennifer L Martin; Martin J Scanlon
Journal:  PLoS One       Date:  2017-03-27       Impact factor: 3.240

Review 7.  Concepts and Core Principles of Fragment-Based Drug Design.

Authors:  Philine Kirsch; Alwin M Hartman; Anna K H Hirsch; Martin Empting
Journal:  Molecules       Date:  2019-11-26       Impact factor: 4.411

8.  Semi-automated single-molecule microscopy screening of fast-dissociating specific antibodies directly from hybridoma cultures.

Authors:  Takushi Miyoshi; Qianli Zhang; Takafumi Miyake; Shin Watanabe; Hiroe Ohnishi; Jiji Chen; Harshad D Vishwasrao; Oisorjo Chakraborty; Inna A Belyantseva; Benjamin J Perrin; Hari Shroff; Thomas B Friedman; Koichi Omori; Naoki Watanabe
Journal:  Cell Rep       Date:  2021-02-02       Impact factor: 9.423

Review 9.  Five Years of the KNIME Vernalis Cheminformatics Community Contribution.

Authors:  Stephen D Roughley
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

10.  Exploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70.

Authors:  Matthew D Cheeseman; Isaac M Westwood; Olivier Barbeau; Martin Rowlands; Sarah Dobson; Alan M Jones; Fiona Jeganathan; Rosemary Burke; Nadia Kadi; Paul Workman; Ian Collins; Rob L M van Montfort; Keith Jones
Journal:  J Med Chem       Date:  2016-05-11       Impact factor: 7.446

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.